Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
-
New pill aims to keep narcolepsy patients awake during the day
Symptom relief CompletedThis study tested a new tablet called ALKS 2680 in 93 adults with narcolepsy type 2, a condition causing severe daytime sleepiness. Participants took either the study drug or a placebo for a set period. The goal was to see if the drug safely improves alertness and reduces sleepin…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated May 26, 2026 07:26 UTC
-
New narcolepsy drug shows promise in reducing sleep attacks and muscle collapse
Symptom relief CompletedThis study tested a new medicine called ALKS 2680 in 92 adults with narcolepsy type 1, a condition that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants stopped their usual narcolepsy medications and took either ALKS 2680 or a placebo for seve…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated May 26, 2026 07:24 UTC